Zacks Research Comments on GSK’s Q1 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Equities researchers at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of GSK in a report released on Wednesday, February 26th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will earn $1.03 per share for the quarter, down from their prior estimate of $1.10. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q2 2025 earnings at $1.05 EPS, Q3 2025 earnings at $1.24 EPS, Q1 2026 earnings at $1.05 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.48 EPS, FY2026 earnings at $4.64 EPS and FY2027 earnings at $5.04 EPS.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

A number of other brokerages have also issued reports on GSK. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $37.33 on Friday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market cap of $77.36 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. The stock’s 50-day moving average is $34.91 and its 200-day moving average is $37.30. GSK has a one year low of $31.72 and a one year high of $45.92.

Hedge Funds Weigh In On GSK

A number of hedge funds and other institutional investors have recently bought and sold shares of GSK. Dorsey & Whitney Trust CO LLC lifted its position in shares of GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after buying an additional 278 shares during the last quarter. Northwest Bank & Trust Co raised its stake in GSK by 1.3% in the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company’s stock valued at $765,000 after acquiring an additional 289 shares during the period. Sunbelt Securities Inc. lifted its holdings in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Mesirow Financial Investment Management Inc. boosted its position in GSK by 2.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares during the period. Finally, Rehmann Capital Advisory Group increased its holdings in shares of GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after purchasing an additional 332 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.21%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is presently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.